Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension

https://doi.org/10.1016/j.bmcl.2014.09.002Get rights and content

Abstract

A novel class of selective inhibitors of ROCK1 and ROCK2 has been identified by structural based drug design. PK/PD experiments using a set of highly selective Rho kinase inhibitors suggest that systemic Rho kinase inhibition is linked to a reversible reduction in lymphocyte counts. These results led to the consideration of topical delivery of these molecules, and to the identification of a lead molecule 7 which shows promising PK and PD in a murine model of pulmonary hypertension after intra-tracheal dosing.

References and notes (23)

  • M.J. van Eis et al.

    Bioorg. Med. Chem. Lett.

    (2011)
  • M. Jacobs et al.

    J. Biol. Chem.

    (2006)
  • T. Thenappan et al.

    Eur. Respir. J.

    (2010)
  • S.A. Antoniu

    Expert Opin. Ther. Targets

    (2012)
  • T. Nagaoka et al.

    J. Appl. Physiol.

    (2006)
  • M. Oka et al.

    Circ. Res.

    (2007)
  • E.Z. Do et al.

    Circ. J.

    (2009)
  • N. Wettschureck et al.

    J. Mol. Med.

    (2002)
  • Y.L. Liu et al.

    Circ. Res.

    (2004)
  • Y. Fukumoto et al.

    Circ. J.

    (2013)
  • H. Fujita et al.

    Heart Vessels

    (2010)
  • Cited by (30)

    • A systematic review on the effects of ROCK inhibitors on proliferation and/or differentiation in human somatic stem cells: A hypothesis that ROCK inhibitors support corneal endothelial healing via acting on the limbal stem cell niche

      2023, Ocular Surface
      Citation Excerpt :

      In 2017, netarsudil (AR-13324; Rhopressa® 0.02%), a ROCK and norepinephrine adrenergic inhibitor [37], was approved for glaucoma treatment in the US [38]. Undesirable systemic effects including hypotension [32] and lymphocytopenia [39] have somewhat curbed the broad introduction of ROCKi into clinical use, though this is less problematic in ophthalmology due to topical delivery where the most frequently reported adverse effect is transient conjunctival hyperemia [40,41]. It appears that some cellular effects of ophthalmic ROCKi may be drug-dependent, as evident from different effects on the corneal epithelium, highlighted by recent cases of reticular bullous epithelial edema associated with netarsudil [42–48] and to a lesser extent, ripasudil [49,50].

    • Design, synthesis and biological evaluations of a long-acting, hypoxia-activated prodrug of fasudil, a ROCK inhibitor, to reduce its systemic side-effects

      2021, Journal of Controlled Release
      Citation Excerpt :

      This drug is currently approved for the treatment of cerebral vasospasm in Japan and China, and reported to be efficacious in the treatment of PAH patients and animal models of PAH [12–14]. However, systemic exposure to fasudil or other Rho-kinase inhibitors induces an undesirable drop in blood pressure, reduces the lymphocyte count, and thus causes a change in the therapeutic window of the drug [8,15,16]. As such, we assume that by avoiding systemic inhibition of Rho kinase, many of the adverse effects of fasudil can be minimized to render it safe for treatment of PAH.

    • Bicyclic 6-6 Systems: Three Heteroatoms 1:2

      2021, Comprehensive Heterocyclic Chemistry IV
    • Glucocorticoid-induced fetal origins of adult hypertension: Association with epigenetic events

      2016, Vascular Pharmacology
      Citation Excerpt :

      Interestingly, dexamethasone stimulates the secretion of endothelin from rat aortic vascular smooth muscle cells, and this may contribute to glucocorticoid-induced hypertension through vasoconstriction and mitogenic processes [85]. A key player in VSMC contraction and coronary vasospasm is Rho-kinase (ROCK) [86,87]. Sustained elevation of serum cortisol is known to trigger coronary vasoconstriction through activation of ROCK [88].

    View all citing articles on Scopus
    View full text